Longeveron to Report 2026 First Quarter Financial Results and Host Conference Call on May 13, 2026
Rhea-AI Summary
Longeveron (NASDAQ: LGVN) will report 2026 first quarter financial results and provide a business update on Wednesday, May 13, 2026 after U.S. market close. The company will host a conference call and webcast the same day at 4:30 p.m. ET.
Conference call number: 1.877.407.0789 with Conference ID 13759888. A replay will be available in the Events & Presentations section of the company website following the call.
Positive
- None.
Negative
- None.
News Market Reaction – LGVN
In the May 6 session, LGVN gained 2.09%, reflecting a moderate positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Previous Conferences,earnings date Reports
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Mar 12 | Earnings call scheduling | Neutral | -0.4% | Announcement of date and time for 2025 full-year results call. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Prior earnings-date scheduling news led to a small negative move, suggesting these announcements have had limited impact on the share price.
Recent news shows LGVN balancing financing, clinical, and compliance milestones. In March 2026, the company announced and then reported 2025 results, alongside a private placement of up to $30 million that initially moved shares sharply. An additional Chinese patent in April 2026 expanded IP but coincided with a modest decline. Today’s earnings-date announcement continues the pattern of routine updates around financial reporting and business progress.
AI-generated analysis. How Rhea-AI works. Not financial advice.
MIAMI, May 05, 2026 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage biotechnology company developing cellular therapy for life-threatening, rare pediatric and chronic aging-related conditions, today announced that it will report 2026 first quarter financial results and provide a business update on Wednesday, May 13, 2026 after the U.S. financial markets close. The Company will host a conference call and webcast the same day at 4:30 p.m. ET.
Conference Call and Webcast Details:
| Conference Call Number: | 1.877.407.0789 |
| Conference ID: | 13759888 |
| Call me™ Feature: | Click Here |
| Webcast: | Click Here |
An archived replay of the webcast will be available on the “Events & Presentations” section of the Company’s website following the conference.
About Longeveron Inc.
Longeveron is a clinical stage biotechnology company developing regenerative medicines to address unmet medical needs. The Company’s lead investigational product is laromestrocel (LOMECEL-B®), an allogeneic mesenchymal stem cell (MSC) therapy product isolated from the bone marrow of young, healthy adult donors. Laromestrocel has multiple potential mechanisms of action encompassing pro-vascular, pro-regenerative, anti-inflammatory, and tissue repair and healing effects with broad potential applications across a spectrum of disease areas. Longeveron is currently pursuing four pipeline indications: hypoplastic left heart syndrome (HLHS), Alzheimer’s disease (AD), Pediatric Dilated Cardiomyopathy (PDCM) and Aging-related Frailty. Laromestrocel development programs have received five distinct and important FDA designations: for the HLHS program - Orphan Drug designation, Fast Track designation, and Rare Pediatric Disease designation; and, for the AD program - Regenerative Medicine Advanced Therapy (RMAT) designation and Fast Track designation. For more information, visit www.longeveron.com or follow Longeveron on LinkedIn, X, and Instagram.
Investor and Media Contact:
Derek Cole
Investor Relations Advisory Solutions
derek.cole@iradvisory.com
